Ginkgo Bioworks Undercuts WuXi on Drug-Testing Prices as It Bets Its Future on Robots, Not Chemists
Q2 2026 earnings call, August 5, 2026: revenue keeps shrinking, but management doubles down on autonomous labs and lands four university contracts
Ginkgo Bioworks used its second-quarter call to make a case that has become the entire thesis for the stock: the company is no longer trying to be a biotech services shop competing on scientist headcount, it is trying to become the infrastructure layer for automated laboratory work, selling both the hardware and a WuXi-style testing service built on top of it. The quarter's financials were unremarkable and, on revenue, outright weak. The strategic disclosures were not.
A direct assault on offshore CRO pricing
The most concrete new information from the call was the launch of ADME-1, a drug-testing service Ginkgo rolled out roughly six weeks before the call that runs the standard five-assay ADME panel (absorption, distribution, metabolism and excretion) used by pharma companies to screen small-molecule drug candidates. CEO Jason Kelly laid out the pricing gap explicitly: Western CRO vendors charge $2,000 to $5,000 per panel, Chinese vendors such as WuXi charge $1,000 to $2,500, and Ginkgo is pricing the same panel, bundled with PK projection and compound management through partners Enveda Bio and Intangible Scientific, at $199. "We think we stand up very well to WuXi in terms of technical capability and throughput, and we kick their butt on price," Kelly said, adding that the service has already signed 16 customers, many of them new logos for Ginkgo, in its first six weeks. Management is positioning this squarely as reshoring, not just a product launch. Kelly cited data showing Chinese biotech startups accounted for roughly none of newly acquired drug assets five years ago, versus 48% last year and more than 50% in the first quarter of this year, and read from a Reddit post by an unemployed bench scientist who was told by a biopharma CEO to consider looking for work in China. The pitch to investors is that Ginkgo's automation is the domestic alternative to that offshoring wave, not a threat to U.S. lab jobs. Chemistry capabilities, including plate-based synthesis and anaerobic chemistry, are coming next, which would let Ginkgo compete on the compound-synthesis side of the CRO business as well, a larger piece of what currently goes to China than testing alone.
Four new university contracts under a $400 million NSF program
Ginkgo disclosed it has been selected to build autonomous labs for Caltech, the University of Maryland and Northwestern University under a National Science Foundation program spending $400 million on a national network of cloud laboratories, plus a separate MIT deal through a different grant. Kelly framed this as validation that the same underlying autonomous lab platform can serve entirely different scientific disciplines: chemical structure data generation at Caltech, protein engineering at Northwestern, biomanufacturing at Maryland and training-focused use at MIT. He called this "the beginning of showcasing that the academic research infrastructure" built around traditional lab benches can be replaced, noting NIH alone spends $40 billion a year on lab-based research and NSF adds more on top of that. Separately, the company's national lab deployment at Pacific Northwest National Laboratory, first installed in December with 13 racks, is being expanded to a 97-rack system under what management called the Genesis mission. On revenue recognition, CFO Steven Coen clarified that hardware sales are recognized on delivery and installation, not on contract signing, meaning the university deals and the PNNL expansion will not show up in reported revenue until systems are actually deployed even though cash may arrive earlier. That is a meaningful modeling point for investors trying to size the near-term financial impact of these wins: the headline logos are real, but the revenue tail is long and back-loaded.
Nebula: doubling capacity in three weeks
Ginkgo's autonomous lab in Boston, Nebula, now runs 105 racks after the company added 50 new racks and had the expanded system running experiments within roughly three weeks, a timeline Kelly described as unheard of in laboratory automation. The system now handles around 30 unique protocols a day submitted directly by scientists rather than automation engineers, with more than 100 protocol instances running across devices at any time. Kelly's framing was that this variability-handling at scale, not the automation itself, is the hard technical problem Ginkgo is trying to solve, drawing a comparison to Waymo versus a fixed subway line: full automation is easy when flexibility is low, and the market Ginkgo is targeting is the 95%-plus of pharma research spending, $60 billion to $80 billion a year industry-wide, that still happens at manual lab benches because robotic systems have not historically been flexible enough for real science.
Financials: burn improving, revenue still falling sharply
Revenue was $20 million in the quarter, down 48% year over year, and $40 million for the first half, down 49%, or roughly 42% excluding a $7.5 million noncash item from a 2025 contract termination. Net loss from continuing operations was $57 million versus $53 million a year ago, and adjusted EBITDA was negative $36 million versus negative $25 million, a deterioration management attributed partly to $14 million in carrying costs on excess leased space that is not generating revenue. Cash burn was $45 million in the quarter versus $38 million a year ago, though first-half burn of $93 million was down 3% from the prior year, aided by a since-completed restructuring. The company reaffirmed full-year 2026 cash burn guidance of $125 million to $150 million and ended the quarter with $302 million in cash plus $87 million in restricted cash. Ginkgo also raised $17 million through its at-the-market equity program during the quarter, kept separate from burn calculations. The company completed the divestiture of its biosecurity business on April 3, which is now reported as discontinued operations, leaving Ginkgo as a single reporting segment going forward. Management declined to provide revenue guidance or break out how much of current revenue comes from autonomous lab sales versus the data points and CRO services business, which limits how precisely investors can size the near-term payoff from the university and national lab wins. Kelly acknowledged the company is "new" to the traditional CRO market it is now targeting with ADME-1 but said "I do like our odds there. It looks real good."